Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
While some say this strategy's failure rate is "too high," it's one step closer to the "white grail" of a shorter 24-week formula.
Read Full NewsDupilumab significantly improves sinus opacification and disease burden in patients with allergic fungal rhinosinusitis.
Oral fecal microbiota transplant raises the amount of peanut that some highly allergic adults can tolerate, serving as proof of concept for microbiome-based food allergy therapy.
Dupilumab yields sustained benefits in terms of nasal congestion, sense of smell, and quality of life in patients with CRSwNP over 24 months in a real-world global registry.
Adults with childhood-onset systemic lupus erythematosus face a strikingly different disease trajectory than those diagnosed later in life, spending less time in the low disease activity state.
Acarizax is now the first house dust mite immunotherapy accepted by the SMC for patients with persistent allergic rhinitis.
1.
Effective Intralesional Melanoma Therapy May Involve Systemic Effects.
2.
Detecting pancreatic cancer through changes in body composition and metabolism
3.
Virtual Reality Travel Reduces Cancer Pain.
4.
EMA Recommends Generic in Advanced/Metastatic Breast Cancer
5.
Immune cell homing hydrogel-based platform captures dendritic cells to process mRNA from cancer vaccines
1.
Know About Lymphangioma: Symptoms, Causes, and Treatments
2.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
3.
Protein S-Palmitoylation in Cancer: A Novel Target in Immunotherapy & Treatment
4.
Different Types of Blood Dyscrasias
5.
Driving Impact: Oncology Pharmaceutical Marketing Strategies in the USA
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
2.
From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2
3.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
4.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
5.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge